Sitemap
- What To Do if You Are Taking Any Prescribed Medication or Supplements
- What To Do if You Are Taking Any Prescribed Medication or Supplements
- What To Do if You Are Taking Any Prescribed Medication or Supplements
- What To Do if You Are Taking Any Prescribed Medication or Supplements
- Combo Asthma Treatment Brings Symptom Relief
- Clinical trial data for Perforomist Inhalation solution
- Clinical trial data for Perforomist Inhalation Solution presented at ...
- Presentation Of Clinical Trial Data For Perforomist Inhalation ...
- FDA approves Dey, L.P.'s NDA for chronic obstructive pulmonary disease ...
- Friday's EuroFile: Boogerd to retire; Valverde ready for Ardennes ...
- Weekly News Summary
- Skyepharma PLC - Completion of Disposal
- What To Do if You Are Taking Any Prescribed Medication or Supplements
- What To Do if You Are Taking Any Prescribed Medication or Supplements
- What To Do if You Are Taking Any Prescribed Medication or Supplements
- What To Do if You Are Taking Any Prescribed Medication or Supplements
- What To Do if You Are Taking Any Prescribed Medication or Supplements
- What To Do if You Are Taking Any Prescribed Medication or Supplements
- What To Do if You Are Taking Any Prescribed Medication or Supplements
- Data show significant asthma control and improved lung function with ...
- Significant asthma control and improved lung function with Symbicort
- The Reclassification of Asthma Based On Subphenotypes
- Astrazeneca Launches A Smarter Approach To Asthma Management In Europe
- What To Do if You Are Taking Any Prescribed Medication or Supplements
- What To Do if You Are Taking Any Prescribed Medication or Supplements
- What To Do if You Are Taking Any Prescribed Medication or Supplements
- Types of medication delivered through inhalers
- Market report: Yesterday's trading
- Novartis, Sky Pharma receive FDA approval for asthma spray Foradil
- SkyePharma PLC announces FDA approves FORADIL(R) CERTIHALER(TM)
- Public Health & Prevention News CME Index
- Asthma Treatment, Info on Asthma Symptoms, Asthma Medication
- DATAMONITOR: Asthma/COPD combo products here to stay
- Mutual Recognition Procedure Completed For Symbicort® Maintenance And ...
- EU Clears New Use for AstraZeneca Asthma Drug
- International Approvals: Foster, Keppra, ATryn
- Novartis, Schering-Plough to develop once-daily drug for asthma
- What To Do if You Are Taking Any Prescribed Medication or Supplements
- What To Do if You Are Taking Any Prescribed Medication or Supplements
- What To Do if You Are Taking Any Prescribed Medication or Supplements
- What To Do if You Are Taking Any Prescribed Medication or Supplements
- What To Do if You Are Taking Any Prescribed Medication or Supplements
- New Delhi, September 12
- Budesonide/formoterol More Cost Effective Than Salmeterol/fluticasone ...
- CME Author: Yael Waknine
- Beta-agonist inhalers more than double death rate in COPD patients ...
- What To Do if You Are Taking Any Prescribed Medication or Supplements
- What To Do if You Are Taking Any Prescribed Medication or Supplements
- What To Do if You Are Taking Any Prescribed Medication or Supplements
- What To Do if You Are Taking Any Prescribed Medication or Supplements
- What To Do if You Are Taking Any Prescribed Medication or Supplements
- Latest News
- Using Maintenance Drugs "As Needed" May Improve Asthma Control
- Risk Of Severe Asthma Attacks Could Be Reduced By Drug Combination
- Growing Warnings About Asthma Drug Added To By Experts
- Drug Combination Could Reduce Risk of Severe Asthma Attacks
- AstraZeneca's Asthma Drug Cuts Severe Attack Risks -Study
- Experts: concerns over the asthma drugs Salmeterol and Formoterol
- Salmeterol can worsen asthma symptoms
- What To Do if You Are Taking Any Prescribed Medication or Supplements
- Asthma Drug Combo Could Be Dangerous Study: Beta Agonists With Inhaled ...
- Asthma Drug Combo Could Be Dangerous
- Asthma Drug Combo Could Be Dangerous
- Drug combo could reduce risk of severe asthma attacks
- Common asthma inhaler causing deaths, researchers assert (press ...
- Asthma Treatment, Info on Asthma Symptoms, Asthma Medication
- US Clears Astra Asthma Drug Symbicort, No Sales Until 2007
- Rotech responds to FDA warning letter
- With severe symptoms, not all inhalers work the same
- Novartis and Schering-Plough in asthma therapy venture
- SGP, Novartis Making Asthma Combo Drug
- UPDATE 2-Novartis, Schering-Plough in asthma dual-drug deal
- SkyePharma PLC Statement Regarding Recent Share Price Movement
- Market Report -- In Play (ROHI)
- Rotech Healthcare Responds to FDA Warning Letter
- Chiesi Group Launch New Product Into UK £80 Million Asthma Market
- 2005/06 Season Anti Doping Pages
- Inquiry into death risk of asthma drug
- Health Alert: bodybugg™
- Inquiry into death risk of asthma drug
- ALTANA Delivers Dynamic 1st Half-Year 2006
- QUICK STUDY : A weekly digest of new research on major health topics
- A question about beta-agonists
- Doctors underestimate emotional impact of COPD Exacerbations
- How asthma sufferers can avoid attacks
- FDA Approvals: Anthelios SX, Symbicort, Oncaspar CME/CE
- These drugs should always be accompanied by inhaled steroids
- The asthma drugs 'that are putting lives at risk'
- AstraZeneca Says FDA Has Approved Asthma Drug Symbicort
- ACAAI: Novel Combo Therapy Safe in Moderate Persistent Asthma
- ACAAI: Combo Beats Budesonide Alone in Asthma
- Skyepharma PLC - Interim Management Statement
- Skyepharma Signs Deals To Terminate Formoterol Certihale Contracts ...
- AstraZeneca and Astellas to co-promote asthma drug in Japan
- Experts Question Study's Asthma Drug Safety Claim
- Novartis Breathes Easier
- Schering-Plough Announces U.S. Filing Of Mometasone Furoate/Formoterol ...
- Clinical Trial Data on the Safety and Efficacy of Concomitant ...
- Critical Therapeutics Completes Phase II Clinical Trial for Zileuton ...
- AstraZeneca Submits an sNDA for Symbicort for the Treatment of Asthma ...
- More Foradil MSN Newsfeeds...
- Study Analyzed SYMBICORT(R) in Children with Persistent Asthma
- Study analyzed SYMBICORT in children with persistent asthma
- RTTNews - Breaking News, financial breaking News, Positive EPS Surprises, Stock research ....
- Patients prefer AZ's Symbicort to Advair in study | Markets | Markets News | Reuters
- New patient satisfaction study with budesonide, formoterol combination therapy
- Webfinanser - AstraZeneca Submits an sNDA for SYMBICORT? for the Treatment of Asthma in Children as Young as Age Six
- News - Budesonide/Formoterol Pressured Metered Dose Better Than Either Agent Alone in Children With Asthma: Presented at ATS
- PharmaLive: Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients
- Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone
- News - Budesonide/Formoterol by Metered-Dose Inhaler Appears Safe in Children With Asthma: Presented at ATS
- RTTNews - Breaking News, financial breaking News, Positive EPS Surprises, Stock research ....
- RTTNews - Quick facts Articles, Positive EPS Surprises, News Analysis, Earnings, Audio News....
- ShareCast - News you can use
- Webfinanser - AstraZeneca Submits an sNDA for SYMBICORT? for the Treatment of Asthma in Children as Young as Age Six
- RTTNews - Breaking News, financial breaking News, Positive EPS Surprises, Stock research ....
- HAYS PHARMA
- AstraZeneca submits an sNDA for Symbicort for treatment of asthma in children as young as 6
- AstraZeneca submits Symbicort sNDA to FDA - MarketWatch
- UPDATE 2-Astra seeks U.S. okay for Symbicort in young kids | Industries | Healthcare | Reuters
- AstraZeneca applied for US Symbicort approval for asthma in 6-11 yr-olds UPDATE - Forbes.com
- AstraZeneca applies for US approval to market asthma treatment Symbicort to children - International Herald Tribune
- Astra seeks US approval for Symbicort - Forbes.com
- PharmaLive: Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients
- Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone
- News: Concomitant use of Perforomist & tiotropium -- significant improvements -- COPD. Genetic Engineering & Biotechnology News - Biotechnology from Bench to Business
- Significant Improvements Shown In Concomitant Use Of Perforomist & Tiotropium For COPD
- COPD: Concomitant Treatment With Nebulized Formoterol Fumarate & Tio - Significant Improvements
- Perforomist-Comparable Pharmacokinetic And Pharmacodynamic Profile To DPI Formulation
- StreetInsider.com - AstraZeneca (AZN) Announces U.S. Launch of SYMBICORT
- PharmaLive: AstraZeneca Announces Symbicort Is Now Available In The U.S.
- AstraZeneca Launches Symbicort in U.S. - Forbes.com
- AstraZeneca Announces SYMBICORT Is Now Available In The US
- Prescription Drugs > SYMBICORT Is Now Available In U.S.
- News: Critical Therapeutics and Dey, L.P. Complete Definitive Co-Promotion Agreement for Perforomist(TM) Inhalation Solution. Genetic Engineering News - Biotechnology from Bench to Business
- News: NicOx Appoints Pascal Pfister MD as Chief Scientific Officer and Strengthens R&D Organization. Genetic Engineering News - Biotechnology from Bench to Business
- Asthma control further improves with combination therapy @ NewKerala.Com News Channel
- PharmaLive: Clinical Trial Data for Perforomist (Formoterol Fumarate) Inhalation Solution Presented at International ATS Conference
- Lyceens.org
- Asthma maintenance and reliever in one inhaler - Healthcare Republic News
- Clinical Trial Data For Perforomist(TM) (Formoterol Fumarate) Inhalation Solution Presented At International ATS Conference
- AstraZeneca Launches New Advance In Asthma Treatment - Symbicort Maintenance And Reliever Therapy (Symbicort SMART)
- Combo Therapy may Be Highly Beneficial in Asthma Control
- Data showed improved quality of life and patient satisfaction with SYMBICORT
- SYMBICORT trial shows improved quality of life with asthma
- Clinical Trial Data For Perforomist (Formoterol Fumarate)
- Clinical Trial Data for Perforomist(TM) (Formoterol Fumarate) Inhalation Solution Presented at International ATS Conference
- Dey, L.P. :: Clinical Trial Data for Perforomist(TM) (Formoterol Fumarate) Inhalation Solution Presented at International ATS Conference
- News - Formoterol Decreases Asthma-Related Hospitalizations and Adverse Events: Presented at ATS
- FDA approves Dey, L.P.'s Perforomist inhalation solution for maintenance treatment of COPD
- AHN | Sufferers Of COPD May Find New FDA-Approved Drug Perforomist A Better Alternative | May 29, 2007
- Log In Problems
- PharmaLive: Clinical Trial Data for Perforomist (Formoterol Fumarate) Inhalation Solution Presented at International ATS Conference
- Clinical Trial Data For Perforomist Inhalation Solution Presented At International ATS Conference
- Bloomberg.com: Germany
- New Publications Confirm Clinical And Scientific Benefits Of Symbicort Smart, A New Approach To Manage Asthma
- Daytrading, Eminis, Forex trading, Swing Trading STOCK ALERT - 552296
- Daytrading, Eminis, Forex trading, Swing Trading STOCK ALERT - 552758
- FDA Approves Dey, L.P.'s Perforomist(TM) (Formoterol Fumarate) Inhalation Solution for Maintenance Treatment of COPD
- FDA Approves Dey, L.P.'s Perforomist(TM) (Formoterol Fumarate) Inhalation Solution For Maintenance Treatment Of COPD
- Clinical trial data for Perforomist Inhalation Solution to be presented at ATS on May 20, 2007
- Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2007
- FDA approves Dey, L.P.'s NDA for chronic obstructive pulmonary disease inhalation solution
- PharmaLive: Clinical Trial Data for Perforomist Inhalation Solution to be Presented at ATS on May 20, 2007
- Presentation Of Clinical Trial Data For Perforomist Inhalation Solution
- FDA Approves Dey, L.P.'s Perforomist Inhalation Solution For Maintenance Treatment Of COPD
- Dey, L.P. :: FDA Approves Dey, L.P.'s Perforomist(TM) (Formoterol Fumarate) Inhalation Solution for Maintenance Treatment of COPD
- Critical Therapeutics' Sales Force Gains Access to a Second Product as FDA Approves Co-Promotion Partner's New Treatment for COPD - PipelineReview.com | Business Intelligence Center
- Clinical trial data for Perforomist Inhalation Solution to be presented at ATS on May 20, 2007
- Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2007
- FDA approves Dey, L.P.'s NDA for chronic obstructive pulmonary disease inhalation solution
- PharmaLive: Clinical Trial Data for Perforomist Inhalation Solution to be Presented at ATS on May 20, 2007
- Presentation Of Clinical Trial Data For Perforomist Inhalation Solution
- FDA Approves Dey, L.P.'s Perforomist Inhalation Solution For Maintenance Treatment Of COPD
- Critical Therapeutics Up on FDA OK - Forbes.com
- PR Newswire Business News: sanofi-aventis: Full-year Guidance Raised on Good 2007 First-Quarter Results - MSN Money
- PharmaTimes WorldNews| Daily pharmaceutical news | Nycomed seeks new partner to promote Alvesco in the USA
- Horrillo fails drugs test: Sport: More Sport: News24
- Ranbaxy beats profit forecast, raises sales outlook | Reuters.com
- BBC NEWS | South Asia | Ranbaxy quarterly profits surge
- Ranbaxy net jumps 79 per cent- Hindustan Times
- Ranbaxy Q1 net rises 79% on European sales-India Business-Business-The Times of India
- Ranbaxy global sales up 23%, net rises 79%-Earnings-Hot Links-The Economic Times
- IndianExpress.com :: Ranbaxys Q1 net jumps 79%
- The Hindu : Business : Robust sales in Europe spur Ranbaxy Q1 net
- Associated Press Business News: Ranbaxy Quarterly Profit Surges 79 Pct. - MSN Money
- www.equitybulls.com - Your One Stop Shop for Financial Services !!!
- Ranbaxy Q1 net profit up 79 pct, beats forecasts| Health| Reuters
- UPDATE 1-Ranbaxy Q1 net beats f'cast, raises sales outlook| Health| Reuters
- Ranbaxy quarterly profit surges 79 pct.
- The Hindu News Update Service
- UPDATE 2-Ranbaxy beats profit forecast, raises sales outlook | Markets News | Reuters.com
- Ranbaxy Quarterly Profit Surges 79 Pct. | Chron.com - Houston Chronicle
- Ranbaxy Quarterly Profit Surges 79 Pct. - Forbes.com
- Ranbaxy 1Q Profit Surges | Chron.com - Houston Chronicle
- Ranbaxy 1Q Profit Surges - Forbes.com
- Ranbaxy 1Q profit surges
- New Publications Confirm Clinical And Scientific Benefits Of
- More Foradil News Articles...
- Formoterol-budesonide inhaler offers advantage; vs. Budesonide alone.(Clinical Rounds)(Brief Article): An article from: Internal Medicine News
- Foradil Certihaler, Celebrex.(New & Approved): An article from: Pediatric News
- Daily budesonide, formoterol works for asthma.(Clinical Rounds)(Clinical report): An article from: Pediatric News
- Budesonide, Formoterol, " Symbicort " : Asthma (Drugs in Context)
- New & Approved.(Brief Article): An article from: Family Practice News
- Formoterol: Fast and Long-lasting Bronchodilation - An International Symposium Held During the First Annual Congress of the European Respiratory Society ... 1991 (International Congress & Symposium S)
- Formoterol: Clinical Profile of a New Long-acting Inhaled B2-Agonist
- Long-acting [Beta]2-agonists: A pharmacological comparison of formoterol and salmeterol
- Formoterol: A Long Acting B2-Agonist for the Management of Asthma : An International Symposium Held During the Joint Meeting of Sep and Sepcr, London
- Formoterol
- FDA panel supports two asthma bronchodilators.(News): An article from: Pediatric News
- Formoterol for asthma maintenance therapy (AAFP home study self-assessment)
- Formoterol - Clinical Profile of a New Long -
- Formoterol-A New-Generation B2-Agonist: An International Symposium Held During the 8th Congress of the European Society of Pneumology, Freiburg, Fede
- FDA panel backs continued sale of 2 bronchodilators: safety concerns prompted panel's review.(News): An article from: Family Practice News
- Formoterol- A New Long-Lasting Bronchodilator
- Formoterol-a New-generation B2-agonist
- Formoterol: A New Long-acting Bronchodilator
- Formoterol Modulite Atimos Forair: Tailoring Treatment to Patient's Needs (Respiration 2005)






